Glucose intolerance states in women with the polycystic ovary syndrome

Journal of Endocrinological Investigation

Volumn 36, Issue 8, 2013, Pages 648-653

  Pasquali, R ^a   Gambineri, A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Insulin resistance; Insulin secretion; Obesity; Polycystic ovary syndrome; Type 2 diabetes

Indexed keywords

DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PREVALENCE; REVIEW; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INCIDENCE; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; PREVALENCE; PROTEINS; SEX HORMONE-BINDING GLOBULIN;

EID: 84885584091     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03346757     Document Type: Review

References (64)

1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005, 352: 1223-36.
2. Rotterdam Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Fertil Steril 2004, 81: 19-25.
3. Pasquali R, Stener-Victorin E, Yildiz BO, et al. PCOS Forum: research in polycystic ovary syndrome today and tomorrow Clin Endocrinol (Oxf) 2011, 74: 424-33.
4. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012, 33: 981-1030.
5. Pasquali R and Gambineri A. Targeting insulin sensitivity in the treatment of polycystic ovary syndrome. Expert Opin Ther Targets 2009, 13: 1205-26.
6. Morales AJ, Laughlin GA, Bützow T, et al. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996, 81: 2854-64.
7. Pasquali R, Gambineri A, Anconetani B, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999, 50: 517-27.
8. Alberti KG, Eckel RH, Grundy SM, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120: 1640-5.
9. Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults: executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-97.
10. Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010, 16: 347-63.
11. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AEPCOS) Society. J Clin Endocrinol Metab 2010, 95: 2038-49.
12. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. Br J Obstet Gynecol 2006, 113: 1148-59.
13. Taponen S, Martikainen H, Järvelin MR, et al. Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. J Clin Endocrinol Metab 2004, 89: 2114-8.
14. Solomon CG, Hu FB, Dunaif A, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001, 286: 2421-6.
15. Cooper GS, Ephross SA, Sandler DP. Menstrual patterns and risk of adult-onset diabetes mellitus. J Clin Epidemiol 2000, 53: 1170-3.
16. Gast GC, Grobbee DE, Smit HA, Bueno-de-Mesquita HB, Samsioe GN, van der Schouw YT. Menstrual cycle characteristics and risk of coronary heart disease and type 2 diabetes. Fertil Steril 2010, 94: 2379-81.
17. Escobar-Morreale HF, Roldán B, Barrio R, Alonso M, Sancho J, de la Calle H, García-Robles R. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2000, 85: 4182-7.
18. Codner E, Soto N, Lopez P, et al. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2006, 91: 2250-6.
19. Mirzaei F, Kazemi N. Prevalence of polycystic ovary syndrome in women with type 2 diabetes in Kerman, Iran. Metab Syndr Relat Disord 2008, 6: 215-7.
20. Amini M, Horri N, Farmani M, et al. Prevalence of polycystic ovary syndrome in reproductive-aged women with type 2 diabetes. Gynecol Endocrinol 2008, 24: 423-7.
21. Kelestimur F, Unluhizarci K, Baybuga H, Atmaca H, Bayram F, Sahin Y. Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus. Fertil Steril 2006, 86: 405-10.
22. Peppard HR, Marfori J, Iuorno MJ, Nestler JE. Prevalence of poly- cystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 2001, 24: 1050-2.
23. Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2000, 52: 81-6.
24. Poretsky L, Cataldo NA, Rosenwaks Z, et al. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1990, 20: 535-82.
25. Tomlinson J, Millward A, Stenhouse E, Pinkney J. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? Diabet Med 2010, 27: 498-515.
26. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84: 165-9.
27. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999, 22: 141-6.
28. Knowler WC, Hamman RF, Edelstein SL, et al. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005, 54: 1150-6.
29. Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000, 15: 785-9.
30. Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome. Int J Gynaecol Obstet 2001, 75: 177-84.
31. Gambineri A, Pelusi C, Manicardi E, et al. Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes 2004, 53: 2353-8.
32. Trakakis E, Basios G, Peppa M, et al. The prevalence of glucose metabolism abnormalities in Greek women with polycystic ovary syndrome. Gynecol Endocrinol 2012, 28: 867-70.
33. Vrbikova J, Dvorakova K, Grimmichova T, et al. Prevalence of insulin resistance and prediction of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome. Clin Chem Lab Med 2007, 45: 639-44.
34. Lee H, Oh JY, Sung YA, Chung H, Cho WY. The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. Endocrine 2009, 36: 326-32.
35. Chen X, Yang D, Li L, Feng S, Wang L. Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome. Hum Reprod 2006, 21: 2027-32.
36. Kurioka H, Takahashi K, Miyazaki K. Glucose intolerance in Japanese patients with polycystic ovary syndrome. Arch Gynecol Obstet 2007, 275: 169-73.
37. Dabadghao P, Roberts BJ, Wang J, Davies MJ, Norman RJ. Glucose tolerance abnormalities in Australian women with polycystic ovary syndrome. Med J Aust 2007, 187: 328-31.
38. Espinós-Gómez JJ, Corcoy R, Calaf J. Prevalence and predictors of abnormal glucose metabolism in Mediterranean women with polycystic ovary syndrome. Gynecol Endocrinol 2009, 25: 199-204.
39. Glintborg D, Henriksen JE, Andersen M, et al. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil Steril 2004, 82: 1570-9.
40. Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Sundström Poromaa I. Diabetes and impaired glucose tolerance in patients with polycystic ovary syndrome-a long term follow-up. Hum Reprod 2011, 26: 1462-8.
41. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 1017-23.
42. Flannery CA, Rackow B, Cong X, Duran E, Selen DJ, Burgert TS. Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI. Pediatr Diabetes 2013, 14: 42-9.
43. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001, 16: 1995-8.
44. Dahlgren E, Johansson S, Lindstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a longterm follow-up focusing on natural history and circulating hormones. Fertil Steril 1992, 57: 505-13.
45. Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. Curr Diab Rep 2006, 6: 77-83.
46. Mani H, Levy MJ, Davies MJ, et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome; a 20 years retrospective cohort study. Clin Endocrinol (Oxf) 2013, 78: 926-34.
47. Gambineri A, Patton L, Altieri A, et al. Polycystic ovary syndrome Is a risk factor for type 2 diabetes. Results from a long-term prospective study. Diabetes 2012, 61: 2369-74.
48. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE. Glucose intolerance in polycystic ovary sindrome - a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007, 92: 4546-56.
49. American Diabetes Association. Summary of revisions for the 2010 clinical practice recommendations. Diabetes Care 2010, 33 (Suppl): S1-3.
50. World Health Organization 2006. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consulation. Geneva: World Health Organization.
51. Kim JJ, Choi YM, Cho YM, et al. Prevalence of elevated glycated hemoglobin in women with polycystic ovary syndrome. Hum Reprod 2012, 27: 1439-44.
52. Celik C, Abali R, Bastu E, Tasdemir N, Tasdemir UG, Gul A. Assessment of impaired glucose tolerance prevalence with hemoglobin A1c and oral glucose tolerance test in 252 Turkish women with polycystic ovary syndrome: a prospective, controlled study. Hum Reprod. 2013, 28: 1062-8.
53. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996, 81: 942-7.
54. Kosova G, Urbanek M. Genetics of the polycystic ovary syndrome. Mol Cell Endocrinol 2013, 373: 29-38.
55. Peng S, Zhu Y, Xu F, Ren X, Li X, Lai M. FTO gene polymorphisms and obesity risk: a meta-analysis. BMC Med 2011, 9:71.
56. Wojciechowski P, Lipowska A, Rys P, et al. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia 2012, 55: 2636-45.
57. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006, 295: 1288-99.
58. Martínez-García MÁ, Gambineri A, Alpañés M, Sanchón R, Pasquali R, Escobar-Morreale HF. Common variants in the sex hormonebinding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. Hum Reprod 2012, 27: 3569-77.
59. Xita N, Georgiou I, Lazaros L, Psofaki V, Kolios G, Tsatsoulis A. The role of sex hormone-binding globulin and androgen receptor gene variants in the development of polycystic ovary syndrome. Hum Reprod 2008, 23: 693-8.
60. Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009, 361: 1152-63.
61. Perry JRB, Weedon MN, Langerberg C, et al. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk for type 2 diabetes. Hum Mol Genetics 2010, 19: 535-44.
62. Wallace IR, McKinley MC, Bell PM, Hunter J. Sex hormone binding globulin and insulin resistance. Clin Endocrinol (Oxf) 2013, 78: 321-9.
63. Wickham EP 3rd, Ewens KG, Legro RS, Dunaif A, Nestler JE, Strauss JF 3rd. Polymorphisms in the SHBG gene influence serum SHBG levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011, 96: E719-27.
64. Galazis N, Afxentiou T, Xenophontos M, Diamanti-Kandarakis E, Atiomo W. Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome. Eur J Endocrinol 2013, 168: R33-43.